These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 32512805)

  • 21. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy.
    Ryan EM; Gorman SP; Donnelly RF; Gilmore BF
    J Pharm Pharmacol; 2011 Oct; 63(10):1253-64. PubMed ID: 21899540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review.
    Kakasis A; Panitsa G
    Int J Antimicrob Agents; 2019 Jan; 53(1):16-21. PubMed ID: 30236954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bacteriophages and its applications: an overview.
    Sharma S; Chatterjee S; Datta S; Prasad R; Dubey D; Prasad RK; Vairale MG
    Folia Microbiol (Praha); 2017 Jan; 62(1):17-55. PubMed ID: 27718043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bacteriophage therapy for management of bacterial infections in veterinary practice: what was once old is new again.
    Squires RA
    N Z Vet J; 2018 Sep; 66(5):229-235. PubMed ID: 29925297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phages as a Cohesive Prophylactic and Therapeutic Approach in Aquaculture Systems.
    Żaczek M; Weber-Dąbrowska B; Górski A
    Antibiotics (Basel); 2020 Sep; 9(9):. PubMed ID: 32882880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy.
    Tagliaferri TL; Jansen M; Horz HP
    Front Cell Infect Microbiol; 2019; 9():22. PubMed ID: 30834237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Associations among Antibiotic and Phage Resistance Phenotypes in Natural and Clinical
    Allen RC; Pfrunder-Cardozo KR; Meinel D; Egli A; Hall AR
    mBio; 2017 Oct; 8(5):. PubMed ID: 29089428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ameliorating the antimicrobial resistance crisis: phage therapy.
    Saha D; Mukherjee R
    IUBMB Life; 2019 Jul; 71(7):781-790. PubMed ID: 30674079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delivering phage therapy per os: benefits and barriers.
    Zelasko S; Gorski A; Dabrowska K
    Expert Rev Anti Infect Ther; 2017 Feb; 15(2):167-179. PubMed ID: 27885865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phage therapy for respiratory infections.
    Chang RYK; Wallin M; Lin Y; Leung SSY; Wang H; Morales S; Chan HK
    Adv Drug Deliv Rev; 2018 Aug; 133():76-86. PubMed ID: 30096336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tracking the phage trends: A comprehensive review of applications in therapy and food production.
    Jaglan AB; Anand T; Verma R; Vashisth M; Virmani N; Bera BC; Vaid RK; Tripathi BN
    Front Microbiol; 2022; 13():993990. PubMed ID: 36504807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bacteriophage Production Models: An Overview.
    García R; Latz S; Romero J; Higuera G; García K; Bastías R
    Front Microbiol; 2019; 10():1187. PubMed ID: 31214139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Understanding and Exploiting Phage-Host Interactions.
    Stone E; Campbell K; Grant I; McAuliffe O
    Viruses; 2019 Jun; 11(6):. PubMed ID: 31216787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isolation of lytic bacteriophage against Vibrio harveyi.
    Crothers-Stomps C; Høj L; Bourne DG; Hall MR; Owens L
    J Appl Microbiol; 2010 May; 108(5):1744-50. PubMed ID: 19886890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bacteriophage Therapy: Clinical Trials and Regulatory Hurdles.
    Furfaro LL; Payne MS; Chang BJ
    Front Cell Infect Microbiol; 2018; 8():376. PubMed ID: 30406049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Possibilities of bacteriophage therapy].
    Skurnik M; Kiljunen S
    Duodecim; 2016; 132(8):712-9. PubMed ID: 27244930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Susceptibilities of multidrug-resistant pathogens responsible for complicated skin and soft tissue infections to standard bacteriophage cocktails].
    Gündoğdu A; Kılıç H; Ulu Kılıç A; Kutateladze M
    Mikrobiyol Bul; 2016 Apr; 50(2):215-23. PubMed ID: 27175494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bacteriophages as Therapeutic and Prophylactic Means: Summary of the Soviet and Post Soviet Experiences.
    Chanishvili N
    Curr Drug Deliv; 2016; 13(3):309-23. PubMed ID: 27090515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Biological characteristics and genomic information of a bacteriophage against pan-drug resistant
    Qi ZY; Yang SY; Dong SW; Zhao FF; Qin JH; Xiang J
    Zhonghua Shao Shang Za Zhi; 2020 Jan; 36(1):14-23. PubMed ID: 32023713
    [No Abstract]   [Full Text] [Related]  

  • 40. Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against
    Rossitto M; Fiscarelli EV; Rosati P
    Front Microbiol; 2018; 9():775. PubMed ID: 29780361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.